Sepio Capital 13F: Adds $58M to Abbott Laboratories (ABT) Stake
Key Points
- Sepio Capital increased its Abbott Laboratories holdings by 296.5% during the quarter, bringing its total stake to 786,102 shares valued at roughly $77.7 million.
- Abbott Laboratories recently traded around $102.53, sitting near its 200-day moving average and below its consensus price target of $120.41.
- Wall Street analysts maintain a strong buy consensus on Abbott, backed by recent price target updates from major firms following the filing date.
Get Abbott Laboratories text alerts
We text you when insiders, Congress, analysts or big funds move on $ABT.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Abbott Laboratories alert may contain errors. Disclosures
Sepio Capital boosted its stake in Abbott Laboratories ABT by 296.5% during the third quarter, according to a Form 13F filing with the SEC on October 22, 2026. The firm acquired an additional 587,854 shares, bringing its total holdings to 786,102 shares. The reported value of the position stood at about $77.7 million at the time of the filing.
ABT
Abbott Laboratories
What Changed in Sepio Capital's Abbott Laboratories Position
The fund expanded its investment significantly from a prior count of 198,248 shares. Abbott Laboratories closed at $102.51 on the filing date. The sharp addition places Sepio Capital among the institutional holders adjusting positions in the healthcare giant during the period.
Other Institutional Activity in Abbott Laboratories
Other major institutional investors adjusted their positions in Abbott Laboratories around the same reporting period. Capital International Investors reduced its holdings by 2,842,222 shares, or 7.6%, ending the quarter with 34,654,113 shares worth about $3.55 billion.
Abbott Laboratories Stock Up 0.1%
Abbott Laboratories recently traded around $102.53 as of October 23, 2026, about equal to its event-day close and right near its 200-day moving average of $102.46. The shares sit 22.3% below their 52-week high of $132.03 and 25.1% above their 52-week low of $81.97. The stock trades about 14.8% below the average analyst price target of $120.41.
Recent Earnings
Abbott Laboratories reported trailing-twelve-month revenue of $46.58 billion and earnings of $2.69 per share. The company posted a net profit margin of 11.6% and a return on equity of 10.6% over the period, with year-over-year revenue growth reaching 13.0%.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
8 target cuts vs 0 raises.
-
EPS & revenue
EPS met estimates. Revenue beat estimates by 0.5%.
-
Profit surprise
EBITDA missed by 43 percent. Operating income missed by 19 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
8 target cuts.
-
Earnings quality
Gross margin up 3.7 points. Positive free cash flow.
Earnings Call Summary
Abbott completed its $2.4 billion acquisition of Exact Sciences on March 23 and is integrating the cancer diagnostics business into its portfolio. First quarter results came in slightly ahead, with sales of $11.2 billion, up 3.7 percent on a comparable basis, though the respiratory season was weaker than expected. The company is seeing early signs of volume recovery in Nutrition after price increases, expects Core Lab Diagnostics to accelerate, and is launching new cardiac devices like the Volt pulsed field ablation catheter and TactiFlex Duo. Management remains confident in second half acceleration but is being cautious on near term market conditions.
Guidance Abbott cut full year earnings guidance from $5.68 to $5.48 per share, reflecting $0.20 of dilution from the Exact Sciences acquisition. The company guided full year revenue growth of 6.5 percent to 7.5 percent on a comparable basis including Exact Sciences. For the second quarter, Abbott expects earnings of $1.25 to $1.31 per share. Management said they are being conservative on respiratory season assumptions and expect acceleration in the second half driven by Nutrition recovery, Core Lab Diagnostics growth, and Exact Sciences integration.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Abbott Laboratories pays an annual dividend of $2.52 per share, translating to a dividend yield of 2.46%. The company maintains a dividend payout ratio of 78.7%, reflecting the portion of earnings returned to shareholders through payouts.
Insider Buying and Selling at Abbott Laboratories
Company insiders executed several transactions prior to the filing. Director John G. Stratton bought 2,000 shares on May 7, 2026, at an average price of $86.82 for a total of $173,640. Officer Louis H Morrone sold 5,850 shares on August 11, 2026, at $109.83 for $642,506. Chief Executive Officer Robert B. Ford disposed of 398,832 shares on August 25, 2026, valued at $46.2 million. Officer John A. Mccoy Jr sold 27 shares on September 2, 2026, at $109.54 for a total of $2,958.
Analysts Set New Price Targets
Wall Street firms updated their views on Abbott Laboratories on October 22, 2026. Citigroup maintained its buy rating while adjusting its price target to $122.00 from $125.00. RBC Capital kept an outperform rating and moved its target to $125.00 from $130.00. Wells Fargo maintained an overweight rating, raising its target to $119.00 from $112.00. JP Morgan kept an overweight rating, shifting its target to $118.00 from $120.00. TD Cowen maintained a buy rating, lowering its target to $118.00 from $135.00. The stock carries an overall strong buy consensus among 26 analysts.
About Abbott Laboratories
Abbott Laboratories operates as a global healthcare company headquartered in Abbott Park, Illinois. Founded to discover, develop, and manufacture health products, the firm serves customers worldwide across four core segments: established pharmaceutical products, diagnostic products, nutritional products, and medical devices. With roughly 122,000 employees, the company supplies critical technologies and treatments across the medical sector.
Bottom Line
Sepio Capital's large stake increase reflects growing exposure to the medical device maker as institutional positioning shifts. Investors will monitor upcoming earnings reports and analyst revisions to gauge whether the stock can bridge the gap toward consensus price targets.
Related Filing Alerts
Source: Sepio Capital's 13F filing on $ABT (Oct 22, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts